0
Signin
countryflagUS

18889881171

AAPL 169.89 0.5147% MSFT 399.04 -2.4495% GOOG 157.95 -1.9553% GOOGL 156.0 -1.9669% AMZN 173.67 -1.6535% NVDA 826.32 3.7087% META 441.38 -10.5613% TSLA 170.18 4.9652% TSM 136.58 2.7149% LLY 724.87 -1.0011% V 275.16 0.0509% AVGO 1294.42 2.9917% JPM 193.37 0.1502% UNH 493.86 1.3462% NVO 125.79 -0.2933% WMT 60.21 0.5679% LVMUY 167.91 -2.1618% XOM 121.35 0.2478% LVMHF 837.0 -2.6461% MA 462.11 -0.0843%

Agile Thrpe

Healthcare US AGRX

0.4USD
-0.0003(0.07%)

Last update at 2024-04-25T18:00:00Z

Day Range

0.370.42
LowHigh

52 Week Range

1.6516.00
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -30.08700M -74.89400M -51.85300M -18.60600M -20.25600M
Minority interest - - - - -
Net income -25.41200M -76.58500M -54.68600M -18.44300M -19.77900M
Selling general administrative 11.86M 14.70M 12.73M 9.00M 8.74M
Selling and marketing expenses 30.37M 43.44M 23.29M - -
Gross profit 4.05M -6.61700M 0.47M - 0.00000M
Reconciled depreciation 1.53M 2.22M 0.28M 0.16M 0.02M
Ebit -41.43400M -71.00500M -49.05300M -18.85800M -18.17300M
Ebitda -41.35400M -70.98000M -48.74400M -18.60600M -18.15000M
Depreciation and amortization 0.08M 0.03M 0.31M 0.25M 0.02M
Non operating income net other - - 0.31M 0.25M 0.40M
Operating income -41.43400M -71.00500M -49.05300M -18.85800M -19.53500M
Other operating expenses 52.32M 75.11M 49.80M 18.86M 18.52M
Interest expense 3.13M 3.91M 3.11M 0.00000M 1.12M
Tax provision -4.67500M - 0.00000M 0.00000M -0.47700M
Interest income 0.08M 0.03M 0.31M 0.25M 0.37M
Net interest income -3.05100M -3.88900M -2.80000M 0.25M -0.75000M
Extraordinary items - - - - -
Non recurring - - - - 1.02M
Other items - - - - -
Income tax expense -4.67500M 1.69M 2.83M -0.16300M -0.47700M
Total revenue 10.88M 4.10M 0.75M 0.00000M 0.00000M
Total operating expenses 45.48M 64.39M 49.52M 18.86M 18.52M
Cost of revenue 6.84M 10.72M 0.28M - 0.00000M
Total other income expense net 11.35M -3.88900M -2.80000M 0.25M -0.99000M
Discontinued operations - - - - -
Net income from continuing ops -25.41200M -74.89400M -51.85300M -18.60600M -19.77900M
Net income applicable to common shares - -74.89400M -51.85300M -18.60600M -19.77900M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 14.24M 39.33M 73.06M 49.54M 22.39M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 1.40M 1.51M 1.45M 0.18M 0.61M
Total liab 19.79M 30.06M 23.73M 3.79M 2.22M
Total stockholder equity -5.54500M 9.27M 49.33M 45.74M 20.17M
Deferred long term liab - - - - -
Other current liab 3.91M 3.56M 3.35M 1.80M 1.34M
Common stock 0.00400M 0.01M 0.00900M 0.00700M 0.00300M
Capital stock 0.00400M 0.01M 0.00900M 0.00700M 0.00300M
Retained earnings -408.70200M -387.11700M -312.22300M -260.37000M -241.55100M
Other liab - - - - -
Good will - - - - -
Other assets - 2.01M 1.90M 0.18M 0.02M
Cash 5.25M 19.14M 14.46M 34.48M 7.85M
Cash and equivalents - - - - -
Total current liabilities 13.39M 29.28M 7.35M 3.79M 2.22M
Current deferred revenue - - - - -
Net debt -3.03500M -1.35100M 2.06M -34.30700M -7.85100M
Short term debt 1.75M 17.01M 0.14M 0.17M -
Short long term debt 1.43M 16.83M - 0.17M -
Short long term debt total 2.21M 17.79M 16.52M 0.17M -
Other stockholder equity 403.15M 396.38M 361.54M 306.11M 262.09M
Property plant equipment - 13.40M 14.24M 14.04M 13.93M
Total current assets 11.36M 23.93M 56.78M 35.32M 8.46M
Long term investments - - - - -
Net tangible assets - 9.27M 49.33M 45.74M 20.17M
Short term investments - 0.00000M 40.01M - -
Net receivables 3.38M 1.53M 0.86M - -
Long term debt - - 16.38M - -
Inventory 1.33M 0.97M - - -
Accounts payable 7.73M 8.71M 3.87M 1.82M 2.22M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - 0.00300M -0.38700M -0.36900M
Additional paid in capital - - - - -
Common stock total equity - - 0.00900M 0.00700M 0.00300M
Preferred stock total equity - - - - -
Retained earnings total equity - - -312.00000M -260.37000M -241.55100M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 2.01M 2.01M 1.90M 0.18M 0.02M
Deferred long term asset charges - - - - -
Non current assets total 2.88M 15.41M 16.28M 14.22M 13.93M
Capital lease obligations 0.79M 0.96M 0.14M 0.17M -
Long term debt total - - 16.38M - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.13300M 39.46M -40.33700M -0.09800M -0.31800M
Change to liabilities - 5.20M 3.64M 1.38M -1.17700M
Total cashflows from investing activities - 39.46M -40.69000M -0.09800M -0.31800M
Net borrowings - - 18.94M 20.00M -10.88800M
Total cash from financing activities 22.18M 30.42M 67.98M 42.41M -10.88800M
Change to operating activities - -1.09800M -2.66900M -0.38500M 0.15M
Net income -25.41200M -74.89400M -51.85300M -18.60600M -19.77900M
Change in cash -13.89700M 4.68M -20.01600M 26.63M -28.10100M
Begin period cash flow 19.14M 14.46M 34.48M 7.85M 35.95M
End period cash flow 5.25M 19.14M 14.46M 34.48M 7.85M
Total cash from operating activities -35.94700M -65.20200M -47.31100M -15.68900M -16.89500M
Issuance of capital stock 39.56M 30.35M 48.43M 42.25M 0.00000M
Depreciation 1.53M 2.22M 0.28M 0.16M 0.02M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory -0.36600M -6.28900M -3.64100M -6.28900M -6.28900M
Change to account receivables -1.84400M -0.66800M -0.86500M -0.86500M -0.86500M
Sale purchase of stock - - 49.04M 42.41M -
Other cashflows from financing activities 4.13M 0.07M 19.55M 0.16M -0.31800M
Change to netincome - 10.32M 4.16M 1.76M 3.60M
Capital expenditures 0.13M 0.27M 0.35M 0.10M 0.32M
Change receivables - - -0.86500M - -
Cash flows other operating - - -2.66900M -0.38500M 0.15M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - -20.01600M 26.63M -28.10100M
Change in working capital -2.13300M -2.85300M 0.11M 0.99M -1.02200M
Stock based compensation 2.49M 3.34M 2.82M 1.76M 3.63M
Other non cash items -12.42900M 1.66M 1.34M -24.29200M 0.28M
Free cash flow -36.08000M -65.47100M -47.66400M -15.78700M -17.21300M

Fundamentals

  • Previous Close 0.40
  • Market Cap4.90M
  • Volume85668
  • P/E Ratio0.27
  • Dividend Yield-%
  • EBITDA-22.33300M
  • Revenue TTM19.98M
  • Revenue Per Share TTM12.32
  • Gross Profit TTM -6.61700M
  • Diluted EPS TTM7.31

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AGRX
Agile Thrpe		 -0.0003 0.07% 0.40 0.27 2.58 0.26 1.78 0.23 -0.3909
ZTS
Zoetis Inc		 2.48 1.64% 153.36 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 -0.37 1.14% 32.07 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 6.97 4.40% 165.33 21.73 14.95 3.16 2.15 3.56 12.82
TAK
Takeda Pharmaceutical Co Ltd ADR		 -0.16 1.21% 13.07 32.67 11.53 0.01 0.87 0.02 0.07

Reports Covered

Stock Research & News

View All

Profile

Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. The company was incorporated in 1997 and is headquartered in Princeton, New Jersey.

Agile Thrpe

500 College Road East, Princeton, NJ, United States, 08540

Key Executives

Name Title Year Born
Mr. Alfred F. Altomari Chairman & CEO 1959
Mr. Geoffrey P. Gilmore Chief Admin. Officer 1966
Dr. Paul Korner M.B.A., M.D. Sr. VP & Chief Medical Officer 1966
Mr. Jason Butch Principal Financial Officer, VP & Chief Accounting Officer NA
Matthew Riley Head of Investor Relations & Corp. Communications NA
Mr. Robert G. Conway M.E. Chief Corp. Planning & Supply Chain Officer 1957
Dr. Elizabeth Ijeoma Onyemelukwe Garner M.D., M.P.H. Consultant 1968
Ms. Amy Welsh Chief Commercial Officer NA
Joseph D'Urso Controller NA
Dr. Kathryn MacFarlane Pharm.D. Advisor 1966

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).